BR112012005208A2 - antiocorpos contra o receptor de glucagon e seu uso - Google Patents

antiocorpos contra o receptor de glucagon e seu uso

Info

Publication number
BR112012005208A2
BR112012005208A2 BR112012005208A BR112012005208A BR112012005208A2 BR 112012005208 A2 BR112012005208 A2 BR 112012005208A2 BR 112012005208 A BR112012005208 A BR 112012005208A BR 112012005208 A BR112012005208 A BR 112012005208A BR 112012005208 A2 BR112012005208 A2 BR 112012005208A2
Authority
BR
Brazil
Prior art keywords
antibodies against
glucagon receptor
glucagon
receptor
antibodies
Prior art date
Application number
BR112012005208A
Other languages
English (en)
Inventor
Eunkyung Lee
Seong-Kyung Seo
Tae-Seong Kim
Original Assignee
Neopharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neopharm Co Ltd filed Critical Neopharm Co Ltd
Publication of BR112012005208A2 publication Critical patent/BR112012005208A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112012005208A 2009-09-08 2009-09-08 antiocorpos contra o receptor de glucagon e seu uso BR112012005208A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2009/005084 WO2011030935A1 (en) 2009-09-08 2009-09-08 Antibodies against glucagon receptor and their use

Publications (1)

Publication Number Publication Date
BR112012005208A2 true BR112012005208A2 (pt) 2016-11-22

Family

ID=43732588

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012005208A BR112012005208A2 (pt) 2009-09-08 2009-09-08 antiocorpos contra o receptor de glucagon e seu uso

Country Status (11)

Country Link
US (1) US9102732B2 (pt)
EP (2) EP3009453A1 (pt)
JP (1) JP2013503626A (pt)
KR (1) KR20120056800A (pt)
CN (1) CN102482350B (pt)
AU (1) AU2009352373B2 (pt)
BR (1) BR112012005208A2 (pt)
CA (1) CA2772590C (pt)
NZ (1) NZ598670A (pt)
RU (1) RU2562110C2 (pt)
WO (1) WO2011030935A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0618925B2 (en) 1991-12-24 2012-04-18 Isis Pharmaceuticals, Inc. Antisense oligonucleotides
JO3756B1 (ar) * 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
WO2013059531A1 (en) * 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
SG11201508264UA (en) * 2013-05-07 2015-11-27 Rinat Neuroscience Corp Anti-glucagon receptor antibodies and methods of use thereof
KR102163529B1 (ko) 2013-06-28 2020-10-12 엑스-바디 인코포레이티드 표적 항원 발견, 표현형 선별 및 표적 세포 특이성 표적 에피토프를 규명하기 위한 그의 용도
CN110058023B (zh) * 2013-09-23 2022-10-14 X博迪公司 用于生成对抗细胞表面抗原的结合剂的方法和组合物
WO2016044337A1 (en) * 2014-09-16 2016-03-24 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies and uses thereof
WO2017055966A1 (en) 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
CN107663239A (zh) * 2016-12-28 2018-02-06 天津天锐生物科技有限公司 一种识别hla‑a2/nlvpmvatv的单域抗体
WO2018140729A1 (en) * 2017-01-27 2018-08-02 Ngm Biopharmaceuticals, Inc. Glucagon receptor binding proteins and methods of use thereof
CN110234352A (zh) * 2017-01-31 2019-09-13 Msm蛋白质技术公司 抗cxcr4抗体
CN110357959B (zh) 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
WO2020023847A1 (en) 2018-07-27 2020-01-30 Ngm Biopharmaceuticals, Inc. Use of glucagon receptor antagonists with immunotherapeutic agent
CN115947849A (zh) 2018-12-21 2023-04-11 江苏恒瑞医药股份有限公司 双特异性蛋白

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005789A1 (en) * 1992-08-28 1994-03-17 Zymogenetics, Inc. Glucagon receptors
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
PE20091674A1 (es) * 2008-03-27 2009-11-04 Lilly Co Eli Antagonistas del receptor de glucagon

Also Published As

Publication number Publication date
CA2772590A1 (en) 2011-03-17
EP3009453A1 (en) 2016-04-20
AU2009352373A1 (en) 2012-04-05
CN102482350A (zh) 2012-05-30
AU2009352373B2 (en) 2016-05-12
US9102732B2 (en) 2015-08-11
CN102482350B (zh) 2015-08-05
EP2475683A1 (en) 2012-07-18
US20130149315A1 (en) 2013-06-13
NZ598670A (en) 2014-05-30
KR20120056800A (ko) 2012-06-04
JP2013503626A (ja) 2013-02-04
EP2475683A4 (en) 2013-04-24
RU2562110C2 (ru) 2015-09-10
CA2772590C (en) 2017-01-03
WO2011030935A1 (en) 2011-03-17
RU2012113554A (ru) 2013-10-20

Similar Documents

Publication Publication Date Title
BR112012005208A2 (pt) antiocorpos contra o receptor de glucagon e seu uso
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
ECSP12011965A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
BR112012002349A2 (pt) composto,e, uso do mesmo
BRPI1007494A2 (pt) composto e uso do mesmo
BRPI1012321A2 (pt) anticorpos anti-vegf e seus usos
BRPI0917535A2 (pt) uso de insulina de ação ultra rápida
BRPI0821668A2 (pt) Uso
BRPI0821110A2 (pt) Anticorpo anti nr-10 e uso do mesmo
BR112012013148A2 (pt) formulação farmacêutica e uso
IL218740A0 (en) New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
BRPI1012560A2 (pt) anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
BRPI1010621A2 (pt) derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
BRPI0906498A2 (pt) Anticorpo ron e seus usos
BRPI0813263A2 (pt) Oxazolidinonas substituídas e seu uso
BRPI0816372A2 (pt) Ácidos 6-fenilnicotínicos substituídos e seu uso
BR112012003066A2 (pt) uso de um anticorpo anti-cd20 defucosilado e composição compreendendo um anticorpo anti-cd20 defucosilado
BRPI0814231A2 (pt) Derivados de pleuromutilina e seu uso como antimicrobianos
BR112012002572A2 (pt) co- polímero catiônico ou anfotérico e seu uso
BRPI1011036A2 (pt) uso
BRPI1005804A2 (pt) unidade redutora de material, uso de unidade redutora de material, e fixador de conteúdo de material reduzido
BR112013014779A2 (pt) composição de filtro solar e uso
BRPI0810498A2 (pt) Composto amida e seu uso
BRPI1011417A2 (pt) uso de malonatos de benzilideno, preparação cosmética,e, malonatos de benzilideno.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements